Longeveron experienced a decrease in revenue and an increased net loss in Q2 2025 compared to the previous year, primarily due to reduced demand for its clinical trial and contract manufacturing services. Despite financial setbacks, the company achieved full enrollment for its pivotal Phase 2b clinical trial (ELPIS II) for HLHS and received FDA approval for its IND application for Pediatric Dilated Cardiomyopathy, signaling significant progress in its development pipeline.
Total revenues for the six months ended June 30, 2025, decreased by 31% to $0.7 million compared to $1.0 million in the same period of 2024.
Net loss increased to $10.0 million for the six months ended June 30, 2025, up from $7.5 million in the prior year, driven by higher operating expenses.
Full enrollment was achieved for the pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel for HLHS, with top-line results anticipated in Q3 2026.
The FDA approved Longeveron’s Investigational New Drug (IND) application for laromestrocel as a potential treatment for Pediatric Dilated Cardiomyopathy, allowing direct progression to a pivotal Phase 2 clinical trial.
Longeveron anticipates increased operating expenses and capital expenditure requirements through 2025 and 2026 due to BLA enabling activities for HLHS. The company is actively seeking additional financing and partnerships to support its development programs, particularly for the Alzheimer's disease program.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance